bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 150KB, Representative positive/negative expression of FGFR1 (A/B), FGFR3c(C/D),FGFR3a(E/F) in NSCLC.
Figure legends for Supplementary Figures from Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Authors: Kong Yan , Si Lu , Li Yiqian , Wu Xiaowen , Xu Xiaowei , Dai Jie , Tang Huan , Ma Meng , Chi Zhihong , Sheng Xinan , Cui Chuanliang , Guo Jun
Published: April 2023

Figure legends for Supplementary Figure S1 and Figure S2
Supplemental Figure Legends from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

The supplemental figure legends.
Supplemental Figure 6 from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

(A) IHC and AgilentTM oligo array expression analysis of prostate and neuroendocrine-associated genes in 24 LuCaP xenograft lines. Mean-centered ratios of genes are colored according to scale (Supplemental Figure 2). LuCaP 49, 93, 145.1 and 145.2 are characterized as neuronal lines while the other 20 lines are adenocarcinoma. Representative IHC images are shown in B.
Supplemental Figure 4 from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

AgilentTM oligo array expression analysis of thirty-seven genes with >2.5-fold differential expression common to 5 CHGA+/SYP+/AR- and 5 CHGA+/SYP+/AR+ CRPC metastases when compared to 61 CHGA- or CHGA+/SYP- CRPC metastases. Mean-centered ratios of genes are colored according to scale (Supplemental Figure 2).
Supplemental Figure 2 from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

A cluster analysis of adenocarcinoma and neuronal CRPC metastases (n=71). The CHGA+/SYP+ sites cluster together (highlighted in orange (AR+) and yellow (AR-)). Genes between CHGA- vs. CHGA+/SYP+ were compared and considered differentially expressed when SAM score was >3 or <-3 and p< 0.005. The resulting 155 genes were hierarchically clustered (centroid linkage) using open source clustering software Cluster 3.0. RetroP: Retroperitoneal, P: Peritoneal. Gene names are listed in Supplemental Table 5. Individual patients are color coded. Mean-centered ratios of genes are colored according to scale.
Supplementary Figure 3 from Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Authors: Apellániz-Ruiz María , Lee Mi-Young , Sánchez-Barroso Lara , Gutiérrez-Gutiérrez Gerardo , Calvo Isabel , García-Estévez Laura , Sereno María , García-Donás Jesús , Castelo Beatriz , Guerra Eva , Leandro-García Luis J. , Cascón Alberto , Johansson Inger , Robledo Mercedes , Ingelman-Sundberg Magnus , Rodríguez-Antona Cristina
Published: April 2023

Supplementary Figure 3. CYP3A4*22 association with paclitaxel-induced neuropathy and paclitaxel dose modifications.
Table S1 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Qiu Fuman , Yang Lei , Ling Xiaoxuan , Yang Rongrong , Yang Xiaorong , Zhang Lisha , Fang Wenxiang , Xie Chenli , Huang Dongsheng , Zhou Yifeng , Lu Jiachun
Published: April 2023

Table S1. All SNPs located in the mature miRNAs sequence.
Supplementary Figure S1 and S2 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 1, 2: Fluorescent-activated cell sorting on malignant patient ascites and OvCSC spheroids
Supplementary Tabes 1, 3 and 4 from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

The attached files include 3 supplemental tables
Supplementary Figure 7 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 7: Sensitivity of Pt224 OvCSC progeny to cisplatin
Supplemental Table 2 from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

This supplemental file is the data base of all 2492 patients with their clinical and pathological factors..
Supplemental Figures 1-3 from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

Supplementary Figure 1: Examples of staining and coring system for cyclin E; Supplementary Figure 2: Examples of LMW-E cyclin E staining; Supplementary Figure 3: REMARK diagram of biospecimen availability for the MDA Lab00-222, NCI TMA, MDA TMA, and UK TMA cohorts.
Supplementary Data from A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer
Authors: Wu Shaoxu , Zheng Junjiong , Li Yong , Yu Hao , Shi Siya , Xie Weibin , Liu Hao , Su Yangfan , Huang Jian , Lin Tianxin
Published: April 2023

Table S1. Pathological characteristics of the patients in our study Table S2. Extracted imaging features Figure S1. Recruitment pathways for patients in this study
Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Authors: Krejcik Jakub , Frerichs Kris A. , Nijhof Inger S. , van Kessel Berris , van Velzen Jeroen F. , Bloem Andries C. , Broekmans Marloes E.C. , Zweegman Sonja , van Meerloo Johan , Musters René J.P. , Poddighe Pino J. , Groen Richard W.J. , Chiu Christopher , Plesner Torben , Lokhorst Henk M. , Sasser A. Kate , Mutis Tuna , van de Donk Niels W.C.J.
Published: April 2023

Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.
Supplemental Table 3 from Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Authors: Brechbuhl Heather M. , Finlay-Schultz Jessica , Yamamoto Tomomi M. , Gillen Austin E. , Cittelly Diana M. , Tan Aik-Choon , Sams Sharon B. , Pillai Manoj M. , Elias Anthony D. , Robinson William A. , Sartorius Carol A. , Kabos Peter
Published: April 2023

Tamoxifen resistant genes up-regulated in ER+ breast cancer cells influenced by CD146neg fibroblasts.
supplemental table 1 from Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
Authors: Van Roy Nadine , Van Der Linden Malaïka , Menten Björn , Dheedene Annelies , Vandeputte Charlotte , Van Dorpe Jo , Laureys Geneviève , Renard Marleen , Sante Tom , Lammens Tim , De Wilde Bram , Speleman Frank , De Preter Katleen
Published: April 2023

detailed information about the patients in this study
Supplementary Tables from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
Authors: Behera Reeti , Kaur Amanpreet , Webster Marie R. , Kim Suyeon , Ndoye Abibatou , Kugel Curtis H. , Alicea Gretchen M. , Wang Joshua , Ghosh Kanad , Cheng Phil , Lisanti Sofia , Marchbank Katie , Dang Vanessa , Levesque Mitchell , Dummer Reinhard , Xu Xiaowei , Herlyn Meenhard , Aplin Andrew E. , Roesch Alexander , Caino Cecilia , Altieri Dario C. , Weeraratna Ashani T.
Published: April 2023

Supplementary Tables
Supplementary Figure Legends from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
Authors: Behera Reeti , Kaur Amanpreet , Webster Marie R. , Kim Suyeon , Ndoye Abibatou , Kugel Curtis H. , Alicea Gretchen M. , Wang Joshua , Ghosh Kanad , Cheng Phil , Lisanti Sofia , Marchbank Katie , Dang Vanessa , Levesque Mitchell , Dummer Reinhard , Xu Xiaowei , Herlyn Meenhard , Aplin Andrew E. , Roesch Alexander , Caino Cecilia , Altieri Dario C. , Weeraratna Ashani T.
Published: April 2023

Legends to supplementary figures
Table S1 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Authors: Abraham Michal , Pereg Yaron , Bulvik Baruch , Klein Shiri , Mishalian Inbal , Wald Hana , Eizenberg Orly , Beider Katia , Nagler Arnon , Golan Rottem , Vainstein Abi , Aharon Arnon , Galun Eithan , Caraco Yoseph , Or Reuven , Peled Amnon
Published: April 2023

Supplementary Table S1A: Part 1 Summary of Baseline Demographic Characteristics Supplementary Table S1B: Part 2 Summary of Baseline Demographic Characteristics
Supplementary Figure 3 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
Authors: Behera Reeti , Kaur Amanpreet , Webster Marie R. , Kim Suyeon , Ndoye Abibatou , Kugel Curtis H. , Alicea Gretchen M. , Wang Joshua , Ghosh Kanad , Cheng Phil , Lisanti Sofia , Marchbank Katie , Dang Vanessa , Levesque Mitchell , Dummer Reinhard , Xu Xiaowei , Herlyn Meenhard , Aplin Andrew E. , Roesch Alexander , Caino Cecilia , Altieri Dario C. , Weeraratna Ashani T.
Published: April 2023

Supplementary Figure 3
supplemental 1 from Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Authors: Cottereau Anne-Ségolène , Lanic Hélène , Mareschal Sylvain , Meignan Michel , Vera Pierre , Tilly Hervé , Jardin Fabrice , Becker Stéphanie
Published: April 2023

Patient clinical characteristics for the whole population and for the cohort with molecular analysis.
Supplementary figure 5-7 from Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle–Invasive Bladder Cancer Patients
Authors: Derré Laurent , Cesson Valérie , Lucca Ilaria , Cerantola Yannick , Valerio Massimo , Fritschi Urs , Vlamopoulos Yannis , Burruni Rodolfo , Legris Anne-Sophie , Dartiguenave Florence , Gharbi Dalila , Martin Virginie , Vaucher Laurent , Speiser Daniel E. , Romero Pedro , Jichlinski Patrice , Nardelli-Haefliger Denise
Published: April 2023

Supplementary Figure S5: Longitudinal evaluation of vaccine-specific T-cells; Supplementary Figure S6: MAGE-A3-specific CD4+ and CD8+ T-cells in each treatment group before vaccination and after 3 and 5 vaccine doses; Supplementary Figure S7: MAGE-A3 specific urine T cells in each treatment group
Supplemental Figures 1-3, Supplementary Tables 1-2 from Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition
Authors: Prabakaran Prashanth J. , Javaid Amal M. , Swick Adam D. , Werner Lauryn R. , Nickel Kwangok P. , Sampene Emmanuel , Hu Rong , Ong Irene M. , Bruce Justine Y. , Hartig Gregory K. , Wieland Aaron M. , Canon Jude , Harari Paul M. , Kimple Randall J.
Published: April 2023

Table S1. List of antibodies used, sources, and application specific details; Table S2. Short tandem repeat loci with patient, passage 1 and passage 5 reads; Figure S1: MYB-NFIB fusion testing ACC patient tumor and PDX; Figure S2: XRT and AMG 232 combination therapy of ACC PDX; Figure S3: Semi-quantitative analysis of Figure 3 B IHC.
Supplementary Figure 3-4 from Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle–Invasive Bladder Cancer Patients
Authors: Derré Laurent , Cesson Valérie , Lucca Ilaria , Cerantola Yannick , Valerio Massimo , Fritschi Urs , Vlamopoulos Yannis , Burruni Rodolfo , Legris Anne-Sophie , Dartiguenave Florence , Gharbi Dalila , Martin Virginie , Vaucher Laurent , Speiser Daniel E. , Romero Pedro , Jichlinski Patrice , Nardelli-Haefliger Denise
Published: April 2023

Supplementary Figure S3: Urinary levels of cytokines/chemokines/growth factors in individual patients before and after BCG instillations; Supplementary Figure S4: Serum anti-MAGE-A3 IgG titers in each individual patient
Supplementary Table 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Authors: Connolly Roisin M. , Li Huili , Jankowitz Rachel C. , Zhang Zhe , Rudek Michelle A. , Jeter Stacie C. , Slater Shannon A. , Powers Penny , Wolff Antonio C. , Fetting John H. , Brufsky Adam , Piekarz Richard , Ahuja Nita , Laird Peter W. , Shen Hui , Weisenberger Daniel J. , Cope Leslie , Herman James G. , Somlo George , Garcia Agustin A. , Jones Peter A. , Baylin Stephen B. , Davidson Nancy E. , Zahnow Cynthia A. , Stearns Vered
Published: April 2023

Global and promoter CpG island demethylation in available paired pre- and post-treatment (8 weeks) hormone-resistant and triple-negative tumor biopsies.
Supplementary Figure 4 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Authors: Connolly Roisin M. , Li Huili , Jankowitz Rachel C. , Zhang Zhe , Rudek Michelle A. , Jeter Stacie C. , Slater Shannon A. , Powers Penny , Wolff Antonio C. , Fetting John H. , Brufsky Adam , Piekarz Richard , Ahuja Nita , Laird Peter W. , Shen Hui , Weisenberger Daniel J. , Cope Leslie , Herman James G. , Somlo George , Garcia Agustin A. , Jones Peter A. , Baylin Stephen B. , Davidson Nancy E. , Zahnow Cynthia A. , Stearns Vered
Published: April 2023

Genomic DNA methylation of tumor biopsies.
Supplementary data from Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Authors: Han Lina , Jorgensen Jeffrey L. , Brooks Chris , Shi Ce , Zhang Qi , Nogueras González Graciela M. , Cavazos Antonio , Pan Rongqing , Mu Hong , Wang Sa A. , Zhou Jin , AI-Atrash Gheath , Ciurea Stefan O. , Rettig Mike , DiPersio John F. , Cortes Jorge , Huang Xuelin , Kantarjian Hagop M. , Andreeff Michael , Ravandi Farhad , Konopleva Marina
Published: April 2023

Supplemental Table 1. Clinical characteristics of non-APL AML patients with MRD data Supplemental Table 2. Flow cytometry panel for MRD Supplemental Table 3. Proportions of AML blasts, CD34+ cells, and CD123+ cells at diagnosis and in remission in 86 patients with AML Supplemental Table 4. Logistic regression models for predictive factors of MRD Supplemental Table 5 A&B. Multivariate Analysis for time to relapse (TTR) Supplemental Table 6. Cytotoxicity of SL-101 in myeloid leukemia cell lines Supplemental Table 7. Demographic and disease characteristics of AML patients for in vitro and in vivo tests Supplemental Figure 1. Gating strategy of CD34+CD123+ blasts in bone marrow samples collected at diagnosis and in remission. Supplemental Figure 2. Expression levels of CD123 and CD131 do not correlate with in vitro response to SL-101 in primary AML samples. Supplemental Figure 3. Phenotypes of primary AML samples post SL-101 treatment. Supplemental Figure 4. SL-101 suppresses AML colony formation but spares normal counterparts. Supplemental Figure 5. SL-101 targets AML leukemia-initiating cells in vivo.
Supplementary Table S4 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Authors: Stelloo Ellen , Nout Remi A. , Osse Elisabeth M. , Jürgenliemk-Schulz Ina J. , Jobsen Jan J. , Lutgens Ludy C. , van der Steen-Banasik Elzbieta M. , Nijman Hans W. , Putter Hein , Bosse Tjalling , Creutzberg Carien L. , Smit Vincent T.H.B.M.
Published: April 2023

Multivariable analysis on the prognostic role of the clinicopathological characteristics, molecular subgroups, and potential other classifiers in all cases of early-stage endometrial cancer (n=834) and in the subset of EC without substantial LVSI, >10% L1CAM, p53 and POLE mutation (n=620).
Legends to supplementary figures and tables from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Authors: Stelloo Ellen , Nout Remi A. , Osse Elisabeth M. , Jürgenliemk-Schulz Ina J. , Jobsen Jan J. , Lutgens Ludy C. , van der Steen-Banasik Elzbieta M. , Nijman Hans W. , Putter Hein , Bosse Tjalling , Creutzberg Carien L. , Smit Vincent T.H.B.M.
Published: April 2023

Legends to supplementary figures and tables
Supplementary Table 3 from A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Authors: Padron Eric , Dezern Amy , Andrade-Campos Marcio , Vaddi Kris , Scherle Peggy , Zhang Qing , Ma Yan , Balasis Maria E. , Tinsley Sara , Ramadan Hanadi , Zimmerman Cassandra , Steensma David P. , Roboz Gail J. , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S.
Published: April 2023

Clinical demographics and characteristics of responses in all patient on study.
Supplementary Figure 2 from A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Authors: Padron Eric , Dezern Amy , Andrade-Campos Marcio , Vaddi Kris , Scherle Peggy , Zhang Qing , Ma Yan , Balasis Maria E. , Tinsley Sara , Ramadan Hanadi , Zimmerman Cassandra , Steensma David P. , Roboz Gail J. , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S.
Published: April 2023

Quantification of quality of life score. (A-F) EORTC-Q30 parsed by predefined subgroups (bottom panel) FACT-Leu trial outcome index (TOI)
Supplementary Figure 1 from A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Authors: Padron Eric , Dezern Amy , Andrade-Campos Marcio , Vaddi Kris , Scherle Peggy , Zhang Qing , Ma Yan , Balasis Maria E. , Tinsley Sara , Ramadan Hanadi , Zimmerman Cassandra , Steensma David P. , Roboz Gail J. , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S.
Published: April 2023

Spaghetti plot demonstrating weekly peripheral counts on study. Absolute (A) and fold change (B) of platelet count. Absolute (C) and fold change (D) of hemoglobin. Absolute (E) and fold change (F) of white blood cell count. Absolute (G) and fold change (H) of monocyte count.
Supplementary File 1. Patients and treatment details from Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers
Authors: Möhrmann Lino , Huang Helen J. , Hong David S. , Tsimberidou Apostolia M. , Fu Siqing , Piha-Paul Sarina A. , Subbiah Vivek , Karp Daniel D. , Naing Aung , Krug Anne , Enderle Daniel , Priewasser Tina , Noerholm Mikkel , Eitan Erez , Coticchia Christine , Stoll Georg , Jordan Lisa-Marie , Eng Cathy , Kopetz E. Scott , Skog Johan , Meric-Bernstam Funda , Janku Filip
Published: April 2023

Supplementary File 1. Patients and treatment details
Supplemental Methods from Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Authors: Müller-Greven Gaëlle , Carlin Cathleen R. , Burgett Monica E. , Ahluwalia Manmeet S. , Lauko Adam , Nowacki Amy S. , Herting Cameron J. , Qadan Maha A. , Bredel Markus , Toms Steven A. , Lathia Justin D. , Hambardzumyan Dolores , Sarkaria Jann N. , Hamerlik Petra , Gladson Candece L.
Published: April 2023

Additional details regarding the methods for cells, reagents, animal studies, immunofluorescence, transcytosis, and ELISA assays.
SFigure 7 from Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Authors: Müller-Greven Gaëlle , Carlin Cathleen R. , Burgett Monica E. , Ahluwalia Manmeet S. , Lauko Adam , Nowacki Amy S. , Herting Cameron J. , Qadan Maha A. , Bredel Markus , Toms Steven A. , Lathia Justin D. , Hambardzumyan Dolores , Sarkaria Jann N. , Hamerlik Petra , Gladson Candece L.
Published: April 2023

Figure S7 shows bevacizumab is transcytosed across normal brain ECs and TECs.
Supplementary Figures 1-8 from Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Authors: Messenheimer David J. , Jensen Shawn M. , Afentoulis Michael E. , Wegmann Keith W. , Feng Zipei , Friedman David J. , Gough Michael J. , Urba Walter J. , Fox Bernard A.
Published: April 2023

Supplementary Figures 1-8
SFigure 3 from Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Authors: Müller-Greven Gaëlle , Carlin Cathleen R. , Burgett Monica E. , Ahluwalia Manmeet S. , Lauko Adam , Nowacki Amy S. , Herting Cameron J. , Qadan Maha A. , Bredel Markus , Toms Steven A. , Lathia Justin D. , Hambardzumyan Dolores , Sarkaria Jann N. , Hamerlik Petra , Gladson Candece L.
Published: April 2023

Figure S3 shows co-localization of different fractions of bevacizumab or human IgG (hIgG) with Rab4 or LAMP1 in CD133+ GBM cells in vitro, and of rat anti-mouse VEGF-A IgG in an established tumor in the immune competent mouse model of GBM in vivo, show similar trafficking patterns.
Supplemental figure 1 from Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Authors: Thielen Noortje , Richter Johan , Baldauf Matthias , Barbany Gisela , Fioretos Thoas , Giles Francis , Gjertsen Bjørn-Tore , Hochhaus Andreas , Schuurhuis Gerrit Jan , Sopper Sieghart , Stenke Leif , Thunberg Sarah , Wolf Dominik , Ossenkoppele Gert , Porkka Kimmo , Janssen Jeroen , Mustjoki Satu
Published: April 2023

MPFC gating strategy
SFigure 1 from Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Authors: Müller-Greven Gaëlle , Carlin Cathleen R. , Burgett Monica E. , Ahluwalia Manmeet S. , Lauko Adam , Nowacki Amy S. , Herting Cameron J. , Qadan Maha A. , Bredel Markus , Toms Steven A. , Lathia Justin D. , Hambardzumyan Dolores , Sarkaria Jann N. , Hamerlik Petra , Gladson Candece L.
Published: April 2023

Figure S1 shows that bevacizumab gains access to the perivascular tumor space and is internalized by tumor cells when administered to an orthotopic xenograft model of GBM and confirmation of cancer stem-like cell markers in vivo.
Supplementary Figures S6-S10 from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure S6: Amplifications in ER-positive/HER2-negative male and female breast cancers. Supplementary Figure S7: Copy number alterations in ER-positive/HER2-negative male and non-lobular female breast cancers. Supplementary Figure S8: Copy number alterations in male and post-menopausal female breast cancers. Supplementary Figure S9: Copy number alterations in male and non-lobular female breast cancers. Supplementary Figure S10: Amplifications in male breast cancers and female breast cancers/ post-menopausal female breast cancers.
Suppementary Table and Legends from Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
Authors: Cercek Andrea , Braghiroli Maria Ignez , Chou Joanne F. , Hechtman Jaclyn F. , Kemeny Nancy , Saltz Leonard , Capanu Marinela , Yaeger Rona
Published: April 2023

Supplementary Table and Legends
Figure S2 from Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
Authors: Cercek Andrea , Braghiroli Maria Ignez , Chou Joanne F. , Hechtman Jaclyn F. , Kemeny Nancy , Saltz Leonard , Capanu Marinela , Yaeger Rona
Published: April 2023

Supplementary Figure 2
Supplementary methods from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

Description of supplementary methods for some general experimental procedures used for this study
Figure legends from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

Supplemental Figure legends
Supplementary Methods and Figure legends from Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
Authors: Au-Yeung George , Lang Franziska , Azar Walid J. , Mitchell Chris , Jarman Kate E. , Lackovic Kurt , Aziz Diar , Cullinane Carleen , Pearson Richard B. , Mileshkin Linda , Rischin Danny , Karst Alison M. , Drapkin Ronny , Etemadmoghadam Dariush , Bowtell David D.L.
Published: April 2023

Additional description of methods for gene suppression studies, Western blot, immunohistochemistry, flow cytometry and cellular assays
Figure S5 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

PIM inhibition blunts the expression of HIF-1 target genes in hypoxia
Supplemental Figure Legends from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

Supplemental Figure Legends
Figure S5 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

A-C): Images of autopsy specimens from an ALK-positive NSCLC patient, demonstrating heterogeneous expression of PD-L1 in multiple sections examined (Diffuse PD-L1 expression in A-B and focal PD-L1 expression in C).
Supplemental Figure 1 from Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Authors: D'Angelo Sandra P. , Shoushtari Alexander N. , Keohan Mary Louise , Dickson Mark A. , Gounder Mrinal M. , Chi Ping , Loo Jennifer K. , Gaffney Leigh , Schneider Lee , Patel Zarine , Erinjeri Joseph Patrick , Bluth Mark J. , Sjoberg Ana , Streicher Howard , Takebe Naoko , Qin Li-Xuan , Antonescu Cristina , DeMatteo Ronald P. , Carvajal Richard D. , Tap William D.
Published: April 2023

Synergy of dasatinib and anti-CTLA-4. Using murine GIST mouse, it was observed that treatment with the KIT-targeted dasatinib for 7 days alone or with chronic anti-CTLA-4 alone decreased tumor volume initially; however tumors rapidly re-grew. Mice treated with KIT-targeted TKI for 7 days and chronic anti-CTLA-4 blockade showed augmentation and durability of the initial response. KITV5880+ mice received dasatinib 15mg/kg i.p. bid (Bristol Myers Squibb) on days 1 through 7, with or without anti-CTLA-5 (BioXcell.) Mice were imaged at baseline and serially during therapy using MRI and volumetric analysis was done using Image K software. Anti-CTLA-4 dosing regimen 200 microgram of clone 9H10 i.p. on day 3, then 100 microgram on day 6, 9 and 12, followed by clone 9D (100 micrograms i.p. every 3 days thereafter.)
Supplementary Figure S3 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas
Authors: Remacha Laura , Comino-Méndez Iñaki , Richter Susan , Contreras Laura , Currás-Freixes María , Pita Guillermo , Letón Rocío , Galarreta Antonio , Torres-Pérez Rafael , Honrado Emiliano , Jiménez Scherezade , Maestre Lorena , Moran Sebastian , Esteller Manel , Satrústegui Jorgina , Eisenhofer Graeme , Robledo Mercedes , Cascón Alberto
Published: April 2023

(A) Aspartate/glutamate ratios assessed by LC-MS in GOT2 KD Hela cells transfected with empty vector (EV), GOT2 wild-type (WT) cDNA, GOT2- c.223T>G cDNA, and GOT2- c.357A>T cDNA. The ratios were reported as means (n=3). Error bars represent standard deviations. A t-test was applied to test for differences between GOT WT and GOT2- c.223T>G and - c.357A>T transfected cells. n.s.: not significant. (B) Succinate/fumarate ratios assessed by LC-MS in OGDHL KD Hela cells transfected with EV, OGDHL WT cDNA, and OGDHL- c.750G>T cDNA. The ratios were reported as means (n=3). Error bars represent standard deviations. A t-test was applied to test for differences. n.s.: not significant
Supplementary Figure S1 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas
Authors: Remacha Laura , Comino-Méndez Iñaki , Richter Susan , Contreras Laura , Currás-Freixes María , Pita Guillermo , Letón Rocío , Galarreta Antonio , Torres-Pérez Rafael , Honrado Emiliano , Jiménez Scherezade , Maestre Lorena , Moran Sebastian , Esteller Manel , Satrústegui Jorgina , Eisenhofer Graeme , Robledo Mercedes , Cascón Alberto
Published: April 2023

(A) Quantitative PCR analysis of RBP1 expression of the 49 tumors included in the study compared to controls comprising five tumors carrying mutation in Krebs cycle genes and five cases carrying mutations in RET or NF1. RU: relative units. (B) SDHB immunohistochemistry of tumor_4 compared to a positive control tumor carrying a non-SDH mutation. The scale bars represent 50μm. (C) Representation of DNA methylation (M_values) of the CpG island probes located within the SDHC locus of tumor_4 compared to a blood sample from the same patient and a control DNA. (D) Immunohistochemical staining of 5-hmC in IDH3B-mutated tumor. Nuclear 5-hmC was observed only in sustentacular and some stromal cells. The scale bar represents 50μm.
Supplemental Figure 4 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Tumor resection enhances infiltration of effector CD4+ and CD8+ T cells
Supplementary data from Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
Authors: Geng Feng , Cheng Xiang , Wu Xiaoning , Yoo Ji Young , Cheng Chunming , Guo Jeffrey Yunhua , Mo Xiaokui , Ru Peng , Hurwitz Brian , Kim Sung-Hak , Otero Jose , Puduvalli Vinay , Lefai Etienne , Ma Jianjie , Nakano Ichiro , Horbinski Craig , Kaur Balveen , Chakravarti Arnab , Guo Deliang
Published: April 2023

Supplementary Figure 1. TIP47 staining represents lipid droplets in cancer cell lines. Supplementary Figure 2. LD number is correlated with Ki67 positive percentage in GBM patient tumor tissues. Supplementary Figure 3. SOAT1 is majorly expressed in GBM patient tumor tissues and cell lines. Supplementary Figure 4. Genetic or pharmacologic inhibition of SOAT1 suppresses lipid droplet formation in GBM cells. Supplementary Figure 5. Genetic or pharmacologic inhibition of SOAT1 does not significantly advance GBM cell cholesterol levels. Supplementary Figure 6. Genetic or pharmacologic inhibition of SOAT1 suppresses SREBP-1 activation and reduces the expression of its downstream targets. Supplementary Figure 7. Inhibition of SOAT1 has no inhibitory effect on LDL uptake.
Supplementary Table 3 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Statistical analysis of in vivo tumor growth delay for dose reduction studies in SH-SY5Y xenografts and Felix-PDX.
Supplementary Table 2 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Statistical analysis of in vivo tumor growth delay and event-free survival in SH-SY5Y and NB-1691 xenografts.
Supplementary Table S3 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Authors: Ascierto Maria L. , Makohon-Moore Alvin , Lipson Evan J. , Taube Janis M. , McMiller Tracee L. , Berger Alan E. , Fan Jinshui , Kaunitz Genevieve J. , Cottrell Tricia R. , Kohutek Zachary A. , Favorov Alexander , Makarov Vladimir , Riaz Nadeem , Chan Timothy A. , Cope Leslie , Hruban Ralph H. , Pardoll Drew M. , Taylor Barry S. , Solit David B. , Iacobuzio-Donahue Christine A. , Topalian Suzanne L.
Published: April 2023

140 Illumina probes corresponding to138 unique genes differentially expressed in regressing (R) vs. progressing (P) cutaneous metastases based on whole genome microarray analysis (fold change magnitude {greater than or equal to}1.7, p value {less than or equal to}0.05 )
Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Authors: Ascierto Maria L. , Makohon-Moore Alvin , Lipson Evan J. , Taube Janis M. , McMiller Tracee L. , Berger Alan E. , Fan Jinshui , Kaunitz Genevieve J. , Cottrell Tricia R. , Kohutek Zachary A. , Favorov Alexander , Makarov Vladimir , Riaz Nadeem , Chan Timothy A. , Cope Leslie , Hruban Ralph H. , Pardoll Drew M. , Taylor Barry S. , Solit David B. , Iacobuzio-Donahue Christine A. , Topalian Suzanne L.
Published: April 2023

Supplementary methods
Supplementary figure legends from Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Authors: Trivedi Sumita , Srivastava Raghvendra M. , Concha-Benavente Fernando , Ferrone Soldano , Garcia-Bates Tatiana M. , Li Jing , Ferris Robert L.
Published: April 2023

Legends for Supplementary Figures 1, 2 and 3
Table S3 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

GSEA results comparing gene pathway expression differences between the IDHmut-Noncodel TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign. ES = Enrichment Score. NES = Normalized Enrichment Score. NOM = Nominal. FDR = False Discovery Rate. FWER = Family-wise error rate.
Supplementary Table 1 from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

Metastatic Capacities of 4T1 and Subclones
Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

The histopathologic feature that correlated most closely with the MRI finding of T2-FLAIR mismatch was the presence of numerous, highly packed microcysts with variable sizes that were noted in regions of moderate or low cell density. These findings were not homogeneous throughout the section, but varied from region to region and were typically associated with edema and neuropil vacuolization (H&E stain, 200X).
Supplementary Material and Methods from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
Authors: Tranchant Robin , Quetel Lisa , Tallet Anne , Meiller Clement , Renier Annie , de Koning Leanne , de Reynies Aurelien , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jaurand Marie-Claude , Jean Didier
Published: April 2023

This file contains the new supplementary Material and Methods.
Supplementary Figure 1 from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

HS131 biodistribution in 4T1 tumor-bearing mice
Supplementary Figures S1-S7 from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
Authors: Tranchant Robin , Quetel Lisa , Tallet Anne , Meiller Clement , Renier Annie , de Koning Leanne , de Reynies Aurelien , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jaurand Marie-Claude , Jean Didier
Published: April 2023

This file contains supplementary Figures S1-S7. Figure S1: YAP1 and WWTR1 gene expression; Figure S2: LATS2 and NF2 siRNA knockdown efficiency; Figure S3: Effect of LATS2/NF2 co-inactivation on MPM cell proliferation, migration and invasion; Figure S4: Analysis of Hippo signaling pathway activity and mTOR expression and phosphorylation in MPM; Figure S5: Activity of the Hippo signaling pathway in the C2LN MPM subgroup; Figure S6: Effect of mTOR inhibitors on MPM cell viability; Figure S7: Validation of a C2LN MPM subgroup biomarker.
Supplemental Tables from Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Authors: Feldmeyer Laurence , Hudgens Courtney W. , Ray-Lyons Genevieve , Nagarajan Priyadharsini , Aung Phyu P. , Curry Jonathan L. , Torres-Cabala Carlos A. , Mino Barbara , Rodriguez-Canales Jaime , Reuben Alexandre , Chen Pei-Ling , Ko Jennifer S. , Billings Steven D. , Bassett Roland L. , Wistuba Ignacio I. , Cooper Zachary A. , Prieto Victor G. , Wargo Jennifer A. , Tetzlaff Michael T.
Published: April 2023

Supplemental Table 1. Relationship Between Merkel Cell Polyoma Virus and Clinicopathologic Parameters. Supplemental Table 2. Univariate Logistic Regression Models for Metastasis to Any Site. Supplemental Table 3. Univariate Logistic Regression for Metastasis to Individual Lymph Node Beyond Sentinel Lymph Node. Supplemental Table 4. Univariate Logistic Regression for Metastasis to Sentinel Lymph Node. Supplemental Table 5. Univariate Logistic Regression for Metastasis to Central Nervous System. Supplemental Table 6. Spearman Correlation Between Cell Density and Age, Tumor Size, Depth of Invasion, and Mitotic Figures. Supplemental Table 7. Relationship Between Gender and Immune Infiltrate. Supplemental Table 8. Merkel Cell Polyoma Virus and Immune Infiltrate. Supplemental Table 9. Immune Infiltrate Cell Density: Descriptive Statistics. Supplemental Table 10. Relationship Between Anatomic Site and Immune Infiltrate. Supplemental Table 11. Relationship Between Lymphovascular Invasion (LVI) and Immune Infiltrate. Supplemental Table 12. Relationship Between Perineural Invasion (PNI) and Immune Infiltrate.
Supplementary Table 1 from Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host
Authors: Park James H. , van Wyk Hester , McMillan Donald C. , Quinn Jean , Clark Jennifer , Roxburgh Campbell S.D. , Horgan Paul G. , Edwards Joanne
Published: April 2023

The relationship between tumour cell STAT3 and pSTAT3 expression and T-lymphocyte density of patients undergoing elective, potentially curative resection of stage I-III mismatch repair competent colorectal cancer
Table S4 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

Excel version of Table S4
Table S1 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

KIR/KIR-ligand genotypes that determine KIR-ligands present vs. KIR-ligand missing status for this report.
Sup. Fig. 5 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

Synergistic effect of Ph+ human cell lines to combined treatment with DHA and ABT-263
Supplementary Figure Legend from RETRACTED: KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition
Authors: Cho Soo-Jeong , Yoon Changhwan , Lee Jun Ho , Chang Kevin K. , Lin Jian-xian , Kim Young-Ho , Kook Myeong-Cherl , Aksoy Bülent Arman , Park Do Joong , Ashktorab Hassan , Smoot Duane T. , Schultz Nikolaus , Yoon Sam S.
Published: April 2023

Supplementary Figure Legend
Figure S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

Expression of MYCN-PARP-DDR pathway genes in MYCN neutral and amplified neuroblastoma tumor samples.
supplementary figure 1 from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Authors: Zhang Jingli , Khanna Swati , Jiang Qun , Alewine Christine , Miettinen Markku , Pastan Ira , Hassan Raffit
Published: April 2023

Semiquantitative assessment of mesothelin expression using H-score in mesothelioma patient derived xenografts.
Supplementary Table 1 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Authors: Magrangeas Florence , Kuiper Rowan , Avet-Loiseau Hervé , Gouraud Wilfried , Guérin-Charbonnel Catherine , Ferrer Ludovic , Aussem Alexandre , Elghazel Haytham , Suhard Jérôme , Der Sakissian Henri , Attal Michel , Munshi Nikhil C. , Sonneveld Pieter , Dumontet Charles , Moreau Philippe , van Duin Mark , Campion Loïc , Minvielle Stéphane
Published: April 2023

Supplementary Table 1: Candidate Gene SNPs in the exploratory study
Supplementary Table S1 from Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Authors: Tan Yee Sun , Sansanaphongpricha Kanokwan , Xie Yuying , Donnelly Christopher R. , Luo Xiaobo , Heath Blake R. , Zhao Xinyi , Bellile Emily , Hu Hongxiang , Chen Hongwei , Polverini Peter J. , Chen Qianming , Young Simon , Carey Thomas E. , Nör Jacques E. , Ferris Robert L. , Wolf Gregory T. , Sun Duxin , Lei Yu L.
Published: April 2023

List of deferentially expressed genes in HNSCC cancer cells resistant to immune killing
Suppl. Fig. 1 from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Flow-cytometry gating strategy for T-cell differentiation and exhaustion markers.